"Tyrosine kinase" refers to a specific type of protein that helps regulate cell growth and division in our body. This protein is responsible for adding a phosphate group to a molecule called tyrosine, which triggers various cellular processes. When working properly,
tyrosine kinases ensure our cells function correctly, but sometimes mutations in these proteins can cause diseases like cancer.
Full definition
«There are currently many exciting therapies including conventional chemotherapies, small molecule inhibitor
tyrosine kinase inhibitors and immune modulating therapies under development in follicular lymphoma,» Westin told Cancer Network.
First - line combination therapy with the programmed death ligand 1 (PD - L1) inhibitor avelumab and the vascular endothelial growth factor
receptor tyrosine kinase inhibitor axitinib resulted in encouraging antitumor activity in patients with previously untreated renal cell carcinoma (RCC) and had a manageable toxicity profile, according to the results of the JAVELIN Renal 100 study published in Lancet Oncology.
Sina Koch (Ehninger, TUD)-- «Aberrant subcellular localization as a potential mechanism contributing to the abnormal signaling of the mutant Flt3 - ITd receptor
tyrosine kinase in acute myeloid leukemia» (2007)
Dissecting specificity in the Janus kinases: the structures of JAK - specific inhibitors complexed to the JAK1 and JAK2
protein tyrosine kinase domains
In fact, numerous animal studies show that soy isoflavones interfere with an enzyme
called tyrosine kinase in the hippocampus, a brain region involved with learning and memory.
Subjects can be enrolled from a local test result if they have any of the following FLT3 mutations: FLT3 internal tandem duplication (ITD), FLT3
tyrosine kinase domain (TKD) / D835 or FLT3 - TKD / I836.
The estimation of EGFR mutation status is essential for the identification of non-small cell lung carcinoma (NSCLC) patients who may benefit from treatment with
EGFR tyrosine kinase inhibitors (TKIs), and hence for improving therapeutic efficacy.
To cite a few instances, polymerase chain reaction (PCR), a molecular method developed over three decades ago, has been widely applied in disease diagnosis, disease mechanism deciphering, and prognosis prediction; the elucidation of
tyrosine kinase activity in cancer cells has led to the development of novel drugs for cancer treatment; and the identification of proteins and genetic molecules by molecular methods as biomarkers for disease diagnosis and prognosis has been drawing great interest.
Howard Hughes Medical Institute researchers have combed through a catalog of all known
tyrosine kinase enzymes to identify new gene mutations that occur in a significant fraction of colon cancers...
We investigated the role of the cytoplasmic
tyrosine kinase JAK2 in patients with a myeloproliferative disorder.
He served as a member of the graduate faculty in the Department of Molecular Biology at Princeton University and spent 10 years at NIH where he madesignificant contributions to the discovery of a class of proteins known
as tyrosine kinase oncogenes as key regulators of the immune system.
Today, it is estimated that about a third of pharmaceutical research and development effort goes into
targeting tyrosine kinase receptors and their signaling pathways for cancer therapies.
HHMI researchers have combed through a catalog of all
known tyrosine kinase genes to identify new mutations that occur in a significant fraction of colon cancers.
Investigated TAM family receptor
tyrosine kinase gene expression in response to small molecule inhibitors in glioblastoma multiforme
(Moussa is listed as an inventor on a patent application that Georgetown University filed related to nilotinib and the use of
other tyrosine kinase inhibitors for the treatment of neurodegenerative diseases.)
(h) Human phospho - receptor
tyrosine kinase array for EphA2, EphB2 and EphB4 ephrin receptors from control BP (shCtr) and BP silenced for Tie2 (siTie2 I and siTie2 II).
Final results of a cohort from a phase II monotherapy trial of quizartinib in acute myeloid leukemia patients showed that more than half of patients 60 years of age and older who harbored an internal tandem duplication in the FMS -
like tyrosine kinase 3 had a composite complete remission.
Western blot analysis of of extracts from cells expressing different
activated tyrosine kinase proteins, using Phospho - PDGF Receptor (Tyr754)(23B2) Rabbit.
Most soy products block the production of thyroid hormone and reduce energy in the body by
inhibiting tyrosine kinases, enzymes involved in the transfer of energy from one molecule to another.
The LIM / Homeodomain Protein Islet1 Recruits
Janus Tyrosine Kinases and Signal Transducer and Activator of Transcription 3 and Stimulates Their Activities
In 2004, we started looking
at tyrosine kinase inhibitors, drugs that block an enzyme that fuels cell growth.
Tobias Heckel (Hoflack, TUD)-- «Revealing
Src tyrosine kinase - dependent signaling pathways in osteoclasts: Implications on actin organization and cell polarity» (2008)
AG490 is a small molecule inhibitor that blocks
several tyrosine kinases including Jak2 (Gazit et al., 1991); Ruxolitinib is a small molecule inhibitor that specifically suppresses Jak kinases (Quintas - Cardama et al., 2010).
An approach often used in treating CML is to block the Bcr - Abl activity
using tyrosine kinase inhibitors (TKIs).
External cues act
on tyrosine kinase proteins embedded in the cell membrane to induce a cascade of signals with a vital role in regulating cell proliferation.
Scanning electron micrograph of the coronary microvasculature of a mouse that has been treated with a small
molecule tyrosine kinase inhibitor of platelet - derived growth factor receptor beta.
The
FLT3 tyrosine kinase is one of the most commonly mutated genes in AML, occurring in about 30 % of AML patients at diagnosis.
In a previous study, Shih, Wang and their colleagues found that paclitaxel resistance may occur because of higher levels of an enzyme found in ovarian cancer cells called
spleen tyrosine kinase, or SYK.
The US Food and Drug Administration (FDA) recently approved the oral
Bruton tyrosine kinase (BTK) inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy.
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) are teaming to revise the evidence - based guideline, «Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and
ALK Tyrosine Kinase Inhibitors.»
The ABL family of
nonreceptor tyrosine kinases, ABL1 (also known as c - Abl) and ABL2 (also known as Arg), links diverse extracellular stimuli to signaling pathways that control cell growth, survival, adhesion, migration, and invasion (1 — 3).
Hunter's work has led to a complete catalogue of the 90 human genes that
encode tyrosine kinases, over half of which have become targets for the development of drugs to treat cancer and other human diseases.
Since many human cancers are driven by mutations
increasing tyrosine kinase activity, these proteins and the molecules they interact with have come center stage as therapeutic targets.
In this first - of - a-kind survey, researchers used a forward - looking approach to screen the genes that
produce tyrosine kinases — reasoning that somewhere in this genomic landscape they might encounter novel mutations that spur colon cancer and other types of cancer.
Another focus was the differential sensitivity of different mutations towards inhibition with
specific tyrosine kinase inhibitors (5).
The initial model for STAT signaling involves a specific cytokine binding to its cognate receptor and promoting the transphosphorylation of receptor associated
tyrosine kinases from the Janus - activated kinase family (JAK).
Hunter's breakthrough, which set the story in motion, was a product of basic research on a chicken RNA tumor virus: the 1979 discovery of the
first tyrosine kinase paved the way for our understanding of how cells perceive their environment and respond appropriately to growth signals.
Therefore, a team led by Vladimir Tesar, MD, PhD (Charles University and General University Hospital, in the Czech Republic) tested the potential of an investigational drug called bosutinib that inhibits a
particular tyrosine kinase called Src / Bcr - Abl.
Phrases with «tyrosine kinase»